Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vemurafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 2/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891936 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL298931 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29355460 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL17784481 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298368 | 0.95 | BRAF (0.91) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL19575141 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298927 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7876722 | 0.94 | BRAF (0.89) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20408711 | 0.94 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL293053 | 0.93 | CYP2C19 (1.00) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712246-B | Bis (hydroxymethyl) pyrrolopyrazine hybrid, preparation method and application thereof | 周美吟 | 2025-05-06 | — | — | CN | claimed |
| CN-119677841-A | Preparation method of dendritic cell progenitor cells and culture medium thereof | 浙江吉量科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20240336972-A1 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-10-10 | — | — | US | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | claimed |
| US-20240240147-A1 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-07-18 | — | — | US | claimed |
| CN-117625531-A | Preparation method of dendritic cell progenitor cells and culture medium thereof | 浙江吉量科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| WO-2023009173-A1 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2022246112-A1 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| CN-114606315-A | Papillary thyroid carcinoma biomarker and application thereof | 浙江省肿瘤医院 | 2022-06-10 | — | — | CN | claimed |
| US-20220177842-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF | OCGENE THERAPEUTICS CORPORATION | 2022-06-09 | — | — | US | claimed |
| US-12630546-B2 | RNF4 targeting compounds and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2026-05-19 | — | — | US | disclosed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12622910-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-12 | — | — | US | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3974453-A2 | AGENTS AND METHODS FOR TREATING DISEASES THAT CORRELATE WITH BCMA EXPRESSION | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3559276-B1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZUERICH (CH) | 2022-03-23 | — | — | EP | disclosed |
| EP-3963109-A1 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-03-09 | — | — | EP | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622910-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | BCL6B, BCL9, BTK | BRAF 20/4885RIPK2 1064/4885RAF1 54/4885 |
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | BRAF 3001/4885RIPK2 1984/4885RAF1 2779/4885 |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | BRAF 3/4885RIPK2 174/4885RAF1 127/4885 |
| US-12630546-B2 | RNF4 targeting compounds and uses thereof | RNF4, RNF168, RNF5 | BRAF 2280/4885RIPK2 2016/4885RAF1 1502/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | BRAF 59/4885RIPK2 3500/4885RAF1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.